Millendo Therapeutics, Inc. (NASDAQ:MLND) has a beta value of 0.48 and has seen 1,437,873 shares traded in the recent trading session. The company, currently valued at $21.52 Million, closed the recent trade at $1.13 per share which meant it lost -$0.05 on the day or -4.11% during that session. The MLND stock price is -222.12% off its 52-week high price of $3.64 and 3.98% above the 52-week low of $1.085. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.91 Million shares traded. The 3-month trading volume is 900.62 Million shares.
The consensus among analysts is that Millendo Therapeutics, Inc. (MLND) is a Hold stock at the moment, with a recommendation rating of 3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 1 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.35.
Millendo Therapeutics, Inc. (NASDAQ:MLND) trade information
Despite being -4.11% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, May 03 when the MLND stock price touched $1.25 or saw a rise of 10.39%. Year-to-date, Millendo Therapeutics, Inc. shares have moved -47.66%, while the 5-day performance has seen it change 13.83%. Over the past 30 days, the shares of Millendo Therapeutics, Inc. (NASDAQ:MLND) have changed -11.8%. Short interest in the company has seen 1.13 Million shares shorted with days to cover at 0.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 342.48% from the levels at last check today. The projected low price target is $5 while the price target rests at a high of $5. In that case, then, we find that the latest price level in today’s session is +342.48% off the targeted high while a plunge would see the stock lose 342.48% from the levels at last check today.
Millendo Therapeutics, Inc. (MLND) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +45.6% over the past 5 years. Earnings growth for 2021 is a modest +40.6%.
Millendo Therapeutics, Inc. (NASDAQ:MLND)’s Major holders
Insiders own 6.28% of the company shares, while shares held by institutions stand at 47.38% with a share float percentage of 50.55%. Investors are also buoyed by the number of investors in a company, with Millendo Therapeutics, Inc. having a total of 48 institutions that hold shares in the company. The top two institutional holders are NEA Management Company, LLC with over 1.77 Million shares worth more than $3.78 Million. As of December 30, 2020, NEA Management Company, LLC held 9.28% of shares outstanding.
The other major institutional holder is Commodore Capital, LP, with the holding of over 925Thousand shares as of December 30, 2020. The firm’s total holdings are worth over $1.98 Million and represent 4.86% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Bridgeway Funds Inc-Small Cap Growth Fund and Vanguard Total Stock Market Index Fund. As of December 30, 2020, the former fund manager holds about 0.86% shares in the company for having 164300 shares of worth $351.6 Thousand while later fund manager owns 163.21 Thousand shares of worth $349.28 Thousand as of December 30, 2020, which makes it owner of about 0.86% of company’s outstanding stock.